290815-01-9

Basic information

• Product Name: Carbamic acid, [(1S)-1-(aminomethyl)-2,2-dimethylpropyl]-, 1,1-dimethylethyl
• Synonyms: Carbamic acid, [(1S)-1-(aminomethyl)-2,2-dimethylpropyl]-, 1,1-dimethylethyl
• CAS NO: 290815-01-9
• Molecular Formula: C₁₁H₂₄N₂O₂
• Molecular Weight: 216.32046
• Product Categories: N-BOC
• Mol File: 290815-01-9.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Carbamic acid, [(1S)-1-(aminomethyl)-2,2-dimethylpropyl]-, 1,1-dimethylethyl(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(1S)-1-(aminomethyl)-2,2-dimethylpropyl]-, 1,1-dimethylethyl(290815-01-9)
• EPA Substance Registry System: Carbamic acid, [(1S)-1-(aminomethyl)-2,2-dimethylpropyl]-, 1,1-dimethylethyl(290815-01-9)

Safety Data

• Hazardous Substances Data: 290815-01-9(Hazardous Substances Data)

Upstream product

• 20859-02-3 L-tert-Leucine 
• 1208257-66-2 tert-butyl [(2S)-1-azido-3,3-dimethylbutan-2-yl]carbamate 
• 290815-00-8 [(1S)-1-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-2,2-dimethylpropyl]carbamic acid 1,1-dimethylethyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 372199-21-8 (S)-tert-butyl (1-amino-3,3-dimethyl-1-oxobutan-2-yl)carbamate 
• 153645-26-2 N-Boc-L-tert-leucinol 

Downstream Products

• 1242073-16-0 [(1S)-2,2-dimethyl-1-[[[(4-methylphenyl)sulfonyl]amino]methyl]propyl]carbamic acid 1,1-dimethylethyl ester 
• 864943-60-2 C₁₉H₃₀N₂O₆S 
• 864943-65-7 C₁₉H₃₁N₃O₆S 

Relevant articles and documents

Construction of Furan Derivatives with a Trifluoromethyl Stereogenic Center: Enantioselective Friedel-Crafts Alkylations via Formal Trienamine Catalysis

An asymmetric Friedel-Crafts alkylation reaction of 2-furfuryl ketones with β-trifluoromethyl enones has been developed via formal trienamine catalysis of a bifunctional primary amine-thiourea substance derived from L-tert-leucine, delivering the furan derivatives incorporating a stereogenic trifluoromethyl (CF3) group in good to high yields with excellent enantioselectivity.

NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF

An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. Th e present invention provides a nicotinamide derivative represented by the follo wing formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl g roup, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each opti onally having at least one substituent; R 3 represents an aryl group or a hetero cyclic group each optionally having at least one substituent; and R 4 and R 5 e ach independently represent a hydrogen atom; and R 2 and R 4 may form a cyc lic amino group optionally having at least one substituent together with the ni trogen atom to which they bind) or a salt thereof, and a pharmaceutical comp osition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

Synthesis of sterically hindered 3,5,5-trimethyl 2,6-dioxo tetrahydro pyrimidine as HCV protease inhibitors

An efficient route for the synthesis of sterically hindered substituted and unsubstituted 2,6-dioxo tetrahydropyrimidines from amine 1 is described. These analogs are active against HCV NS3 serine protease. The biological data for some of the representati